The prevention of pain from sickle cell disease by trandolapril.
A 48-year-old African-American woman with both sickle cell anemia and chronic pain was treated with a hydrophobic angiotensin I-converting enzyme (ACE) inhibitor. This resulted in the complete resolution of her pain. When the ACE inhibitor was deliberately stopped, her pain recurred, only to cease again after the ACE inhibitor was deliberately resumed. The activation of ACE may be an early step in the arterial vaso-occlusion typical of sickle cell disease.
Williams
R Michael
RM
Stanislaus Cancer Treatment Research Foundation, Modesto, CA, USA.
Moskowitz
David W
DW
D001741:Black or African American / Q000235:genetics; D000755:Anemia, Sickle Cell / Q000201:enzymology / Q000208:ethnology / Q000503:physiopathology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D015687:Cell Hypoxia / Q000187:drug effects; D002908:Chronic Disease; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D007703:Peptidyl-Dipeptidase A / Q000235:genetics; D014661:Vasoconstriction / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; C052035:trandolapril; D007703:Peptidyl-Dipeptidase A